Comparative evaluation of chronic iron overload in the application of iron preparations in the sub-toxic doses


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Iron supplements used for the treatment of iron deficiency anemia differ in their safety. Untike organic iron salts, inorganic iron compounds such as oxides, hydroxides and sulfates do not have high bioavailability and significantly overload tissues with insoluble iron oxides. In this paper, an experimental study of iron supplementation on the basis of iron hydroxides in the composition polymaltose complex (Maltofer®) and iron sulfate is reported. Oral administration of iron sulfate for 2 months induced chronic iron overload, reflect both by histological damage by hemosiderin in parenchyma of liver, kidneys and brain, by an increase of ALT in blood and of protein levels in the urine. In comparison with ferrous sulfate, Maltofer has advantages for chronic use: hemosiderin deposits were absent in brain and in kidney tissue; small deposits of hemosiderin in the liver were found only in intralobular sinus capillaries, but not in hepatocytes.

Full Text

Restricted Access

About the authors

Olga Anatolievna Nazarenko

Ivanovo state medical academy

PhD, associate professor, Department of pharmacology and clinical pharmacology

Olga Alekseevna Gromova

Ivanovo state medical academy

Email: unesco.gromova@gmail.com
MD, professor of the Department of pharmacology and clinical pharmacology

Vadim Igorevich Demidov

Ivanovo state medical academy

PhD, senior researcher of the research center

Ivan Yurievich Torshin

Moscow institute of physics and technology (state university)

candidate of physico-mathematical sciences, associate professor of the Department of intelligent systems

Irina Konstantinovna Tomilova

Ivanovo state medical academy

MD, head of the Department of chemistry

Yelena Lvovna Aleksakhina

Ivanovo state medical academy

candidate of chemical sciences, scientific adviser of the Research center

References

  1. Дворецкий Л.И. Железодефицитные анемии. М.: Ньюдиамед, 1998. 37 с. [Dvoretsky L.I. Iron deficiency anemia. Moscow: Newdiamed, 1998. 37 p. (in Russian)]
  2. Стуклов Н.И., Чистякова А.В. Диагностика и выбор тактики лечения железодефицитной анемии у больных гастроэнтерологического профиля. РМЖ. 2015;13:781-7. [Stuklov N.I., Chistyakova A.V. Diagnosis and choice of treatment of iron deficiency anemia in patients of the gastroenterological profile. Russian medical journal. 2015;13:781-7 (in Russian)]
  3. Воробьев А.И. Руководство по гематологии. М.: Медицина, 1985. 368 с. [Vorobiev A.I. Manual of hematology. M.: Medicine, 1985. 368 p. (in Russian)]
  4. Воробьев П.А. Анемический синдром в клинической практике. М.: Ньюдиамед, 2001. 168 с. [Vorobiev P.A. Anemic syndrome in clinical practice. Moscow: Newdiamed, 2001. 168 p. (in Russian)]
  5. Громова О.А., Торшин И.Ю., Хаджидис А.К. Нежелательные эффекты сульфата железа в акушерской, педиатрической и терапевтической практике. Земский врач. 2010;2:1-8. [Gromova O.A., Torshin I.Yu., Hajidis A.K. Adverse effects of iron sulfate in obstetric, pediatric and therapeutic practice. A country doctor. 2010;2:1-8 (in Russian)]
  6. Громова О.А., Торшин И.Ю., Минушкин О.Н., Диброва Е.А., Каримова И.М. Кустова. Е.В. Об эффективности и молекулярных механизмах действия препарата Лаеннек в лечении патологических состояний печени, связанных с отложением железа в печени. Медицинский журнал «Дело жизни». 2015;1 (1 ):44-51. [Gromova O.A., Torshin I.Yu., Minushkin O.N., Dibrova Ye.A., Karimova I.M., Kustova Ye.V. On the efficiency and molecular mechanisms of action of the drug Laennec in treatment of pathological conditions of the liver associated with iron deposition in the liver. Medical journal «Business of life». 2015;1(1):44-51 (in Russian)]
  7. Токарев Ю.Н., Сеттарова Д.А., Сметанина Н.С., Максимов В.А., Румянцев А.Г. Болезни перегрузки железом (гемохроматозы). Рук. для врачей. Под ред. А.Г. Румянцева, Ю.Н. Токарева. М.: Медпрактика-М, 2004. 328 с. [Tokarev Yu.N., Settarova D.A., Smetanina N.S., Maksimov V.A., Rumyantsev A.G. Diseases of iron overload (hemochromatosis). Ed. A.G. Rumyantsev, Yu.N. Tokarev. Moscow: Medpraktika-M, 2004. 328 p. (in Russian)]
  8. Громова О.А., Торшин И.Ю., Гришина Т.Р., Томилова И.К. Значение использования препаратов железа и его молекулярных синергистов для профилактики и лечения железодефицитной анемии у беременных. Российский вестник акушера-гинеколога. 2015;4:85-94. [Gromova O.A., Torshin I.Yu., Grishina T.R., Tomilova I.K. Value of the use of iron preparations and its molecular synergists for the prevention and treatment of iron deficiency anemia in pregnant women. The Russian Bulletin of the obstetrician-gynecologist. 2015;4:85-94 (in Russian)]
  9. Sullivan J.L., Mascitelli L. Current status of the iron hypothesis of cardiovascular diseases. Recenti. Prog. Med. 2007;98(7-8):373-7.
  10. Geisser P., Baer M., Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992;42(12):1439-52.
  11. WHO/NHD. Iron Deficiency Anaemia. Assessment, Prevention and Control: A guide for programme managers, 2001.
  12. Милованова Л., Милованов Ю., Козловская Л. Железа (III) гидроксид полимальтозоат - препарат нового поколения для лечения железодефицитной анемии. Врач. 2013;1:54-7. [Milovanova L., Milovanov Yu., Kozlovskaya L. Iron (III) hydroxide polymaltose complex, a new-generation drug, for the treatment of iron-deficiency anemia. Doctor. 2013;1:54-7 (in Russian)]
  13. Громова О.А., Рахтеенко А.Ю., Громова М.А. Справочник поликлинического врача. Глава «Железодефицитная анемия». М.: Бионика-Медиа, 2015. 573 с. [Gromova O.A., Rotenko A.Yu., Gromov M.A. Handbook of outpatient physician. Chapter «Iron deficiency anemia». Moscow: Bionika-Media, 2015. 573 p. (in Russian)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies